How did Gilead Sciences' revenue and expenses trends shift in Q4 2024?

**Gilead Sciences experienced a shift in revenue and expense trends during Q4 2024.** Here's a detailed analysis:

1. **Revenue Trends**:
- Gilead Sciences saw a year-over-year revenue growth of 0.06% in Q4 2024, with the total revenue amounting to $7.57 billion. This growth was primarily driven by higher sales in the HIV segment, which includes products like Biktarvy, as well as in Veklury (remdesivir) and Oncology.
- The company's product sales, excluding Veklury, increased by 7% year-over-year to $6.8 billion. Biktarvy, in particular, saw a 13% year-over-year growth in sales, reaching $3.5 billion.
- Oncology sales grew by 6% year-over-year to $816 million, with Trodelvy's sales rising by 17%.
2. **Expense Trends**:
- There was no available data on operating expenses for Q4 2024. However, it is important to note that Gilead Sciences has been managing expenses effectively, as evidenced by the company's overall financial performance and the reduction in operating expenses in previous quarters.
- The company's operating income for Q3 2024 was $888 million, compared to $2,623 million in the same period in 2023. This indicates a decrease in operating expenses as a percentage of revenue.
3. **Comparative Analysis**:
- Gilead Sciences' revenue growth in Q4 2024 was relatively modest compared to the previous quarter, where the company reported a 6% increase in revenue for the nine months ended September 30, 2024.
- The EPS of $1.45 anticipated for Q4 2024 by Zacks Research analysts suggests a potential decline from the previous quarter's EPS of $2.01.
4. **Market Performance and Outlook**:
- Despite the slight revenue growth, Gilead Sciences' stock has seen a positive change, with a 2.2% increase in its last price.
- Analysts have set a consensus estimate for Gilead Sciences' current full-year earnings at $3.78 per share, indicating confidence in the company's financial performance.

In conclusion, Gilead Sciences showed steady revenue growth in Q4 2024, driven by strong sales in key segments such as HIV and Oncology. The company's focus on disciplined expense management is evident, although specific expense data for Q4 2024 is not available. The overall financial performance and market outlook suggest that Gilead Sciences remains a robust player in the biopharmaceutical sector.